The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism

Klebe, S., Golmard, J.-L., Nalls, M. A., Saad, M., Singleton, A. B., Bras, J. M., Hardy, J., Simon-Sanchez, J., Heutink, P., Kuhlenbaumer, G., Charfi, R., Klein, C., Hagenah, J., Gasser, T., Wurster, I., Lesage, S., Lorenz, D., Deuschl, G., Durif, F., ... Wood, N. W. (2013). The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism. *Journal of neurology, neurosurgery, and psychiatry*, 84(6), 666-673. https://doi.org/10.1136/jnnp-2012-304475

Published in:
*Journal of neurology, neurosurgery, and psychiatry*

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
*Link to publication record in Queen's University Belfast Research Portal*

**Publisher rights**
Copyright 2013 the authors. This is an open access Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/3.0/), which permits use, distribution and reproduction for non-commercial purposes, provided the author and source are cited.

**General rights**
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person’s rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
RESEARCH PAPER

The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson’s disease with a sexual dimorphism

Stephan Klebe,1,2,3,4,5,6,7 Jean-Louis Golmard,8 Michael A Nalls,9 Mohamad Saad,10,11 Andrew B Singleton,9 Jose M Bras,12 John Hardy,12 Javier Simon-Sanchez,9,13 Peter Heutink,13 Gregor Kuhlenbäumer,14 Rim Charfi,15,16 Christine Klein,17 Johann Hagenah,17 Thomas Gasser,18,19 Isabel Wurster,18,19 Suzanne Lesage,1,2,3 Delia Lorenz,20 Günther Deuschl,20 Franck Durif,21 Pierre Pollak,22 Philippe Damier,23 François Tison,24 Alexandra Durr,1,2,3,4 Philippe Amouyel,25,26,27 Jean-Charles Lambert,25,26,27 Christophe Tzourio,28,29 Cécilia Maubaret,30 Fanny Charbonnier-Beaupel,1,2,3 Khadija Tahiri,1,2,3 Marie Vidalhiet,2,3,6,31 Maria Martinez,10,11 Alexis Brice,1,2,3,4,6 Jean-Christophe Corvol,1,2,3,5,15 French Parkinson’s Disease Genetics Study Group and the International Parkinson’s Disease Genomics Consortium (IPDGC)

ABSTRACT

The catechol-O-methyltransferase (COMT) is one of the main enzymes that metabolise dopamine in the brain. The Val158Met polymorphism in the COMT gene (rs4680) causes a trinomial distribution of high (Val/Val), intermediate (Val/Met) and low (Met/Met) enzyme activity. We tested whether the Val158Met polymorphism is a modifier of the age at onset (AAO) in Parkinson’s disease (PD). The rs4680 was genotyped in a total of 16,609 subjects from five independent cohorts of European and North American origin (5868 patients with PD and 10,723 healthy controls). The multivariate analysis for comparing PD and control groups was based on a stepwise logistic regression, with gender, age and cohort origin included in the initial model. The multivariate analysis of the AAO was a mixed linear model, with COMT genotype and gender considered as fixed effects and cohort and cohort-gender interaction as random effects. COMT genotype was coded as a quantitative variable, assuming a codominant genetic effect. The distribution of the COMT polymorphism was not significantly different in patients and controls (p=0.22). The Val allele had a significant effect on the AAO with a younger AAO in patients with the Val/Val (57.1±13.9, p=0.03) than the Val/Met (57.4±13.9) and the Met/Met genotypes (58.3±13.5). The difference was greater in men (1.9 years between Val/Val and Met/Met, p=0.007) than in women (0.2 years, p=0.81). Thus, the Val158Met COMT polymorphism is not associated with PD in the Caucasian population but acts as a modifier of the AAO in PD with a sexual dimorphism: the Val allele is associated with a younger AAO in men with idiopathic PD.

INTRODUCTION

Parkinson’s disease (PD) is a neurodegenerative disorder characterised by the loss of dopaminergic neurons in the mesencephalon. The diagnosis of PD is usually made when patients first notice symptoms of motor dysfunction (bradykinesia, tremor and rigidity) that are related to loss of the dopaminergic innervation in the striatum. However, the dopaminergic deficiency in the mesencephalon remains clinically silent until the concentration of dopamine has decreased by 60–80% in the striatum, and until 30–40% loss of dopaminergic neurons has been reached (1–7). Compensatory mechanisms may thus be involved to explain this delay in the occurrence of motor symptoms.

In the central nervous system, two main enzymes, the monoamine oxidase B (MAOB) and the catechol-O-methyltransferase (COMT) metabolise dopamine. The human COMT gene (OMIM 116790) is localised on chromosome 22q11.2. The distribution of COMT activity in the population and in families indicates that it is regulated by a single autosomal locus with two codominant alleles.1 2 The substitution of valine (Val) by methionine (Met) at codon 158 (Val158Met) in the membrane-bound isoform, corresponding to codon 108 in the soluble form, results in a trinomial distribution of high, low and intermediate enzymatic activity. COMT activity is threefold to fourfold higher in the liver and red blood cells of 158Val patients than in those with the 158Met variant.3 4 There are ethnic differences in the distribution of the Val158Met genotype.5 About 25% of the Caucasian population is homozygous for the low activity variant (Met/Met), 25% is homozygous for the high activity variant (Val/Val) and 50% has the intermediate activity variant (Val/Met).6 7

The influence of the COMT Val158Met polymorphism on non-motor symptoms in PD, particularly cognitive functions, has been studied8–11...
but little is known about its effect on motor symptoms. In the present study, we hypothesise that COMT activity might modulate the age at onset (AAO) of motor symptoms in PD by modifying the bioavailability of the remaining endogenous dopamine in the striatum. Using the COMT Val158/108Met polymorphism as a surrogate marker of enzyme activity, we performed an association study in 16,609 patients and controls of European and North American origin.

PATIENTS AND METHODS

French samples

Subjects with PD (n=1031) were recruited through the French network for the study of Parkinson’s disease genetics associating 15 university hospitals across France. All patients were of European origin. Definite and probable PD was defined according to the UK Parkinson’s Disease Society Brain Bank (UKPDSBB).12 The healthy controls (n=2061) of the French sample came from either the French Three-City (3C) cohort (n=1933)13 or the Parkinson’s disease genetics network (n=128). The participants of the 3C cohort were noninstitutionalised subjects over 65 years of age, randomly selected from the electoral rolls of three French cities. The control subjects were matched for gender with patients with PD.

German samples

The German samples consisted of three independent cohorts (Kiel, Lübeck and Tübingen). Patients with PD (n=648) and healthy controls (n=688) from the Kiel sample were from the Population Based Assessment of Genetic Risk Factors for PD study performed in northern Germany in cooperation with the Populationsgenetik (POPGEN) biobank.14 All participating patients with PD were diagnosed by board certified neurologists according to the UKPDSBB Criteria.12 Controls (n=688), also obtained by POPGEN, were matched to the cases by gender and geographical origin and were screened to confirm the absence of PD. The Lübeck sample consisted of 525 cases and 223 healthy controls collected in specialised outpatient clinics. All patients underwent a detailed neurological examination by a movement disorder specialist and the diagnosis of PD was established clinically according to the UKPDSBB.12 The controls underwent the same neurological examination as the patients. The PD cases (n=662) for the Tübingen cohort were collected by movement disorders specialists at the Universities of Munich and Tübingen, according to the UKPDSBB.12 Sample collection from controls (n=767) was performed as part of the Prospective validation of risk markers for the development of idiopathic Parkinson’s disease (Idiopathic Parkinson Kohorte Syndroms, PRIPS) study in Tübingen.

International Parkinson’s Disease Genomics Consortium

Genome-wide association studies-based data from three contributing cohorts from the International Parkinson’s Disease Genomics Consortium was used in this study and have been described in detail elsewhere.15–19 This includes 937 cases of PD and 3033 controls from the US samples from the National Institute on Aging cohort, 744 cases and 2019 controls from the Dutch cohort, and 1648 cases and 2699 controls from the UK cohort.15–19 All these studies were carried out in accordance with the Declaration of Helsinki and the rules for clinical good practice. All participants gave their informed consent. The local Ethical Committees approved the studies.

AAO definition

AAO was systematically determined at the time of inclusion by a retrospective interview. The AAO was defined as the first PD-related motor symptom (akinesia, tremor or rigidity) experienced by the patient for the French, Lübeck and Tübingen cohorts, and by the age at which PD was first diagnosed for the Kiel sample and the International Parkinson’s Disease Genomics Consortium cohorts.

Genotyping

The COMT polymorphism G185A (rs4680) was analysed by an allelic discrimination Taqman assay (Applied Biosystems PRISM 7900 sequence detection system, Applied Biosystems, Foster City, USA) for the German samples or extracted from DNA array studies as described elsewhere.15 16 20–24

Statistical analysis

Descriptive statistics used numbers and percentages as qualitative variables and means and SDs as quantitative variables.

Relationships between qualitative variables were tested using χ² tests and comparisons between means of quantitative variables were performed using Student t tests for two groups and unbalanced analysis of variance (ANOVA) for more than two groups. The multivariate analysis for comparing PD and control groups was based on a stepwise logistic regression, with all variables included in the model and variables statistically significant with p<0.05 from the Wald test retained in the final model. The multivariate analysis of the AAO was first based on a mixed linear model, with the COMT genotype and gender considered as fixed effects and cohort and cohort-gender interaction considered as random effects. In a second step, two distinct models were fitted, one for men and one for women, with the COMT genotype as the fixed effect and the cohort as the random effect. In all mixed linear models, the COMT genotype was coded as a quantitative variable, namely a difference in ‘1’ alleles. Hardy-Weinberg equilibrium was tested using χ² tests in each sample. All tests were two-sided, with a p value of 0.05 considered statistically significant. Computations were performed using the SAS V9 statistical package.

RESULTS

Characteristics of patients and controls

A total of 17,665 subjects were available (6177 patients with PD and 11,488 controls). Due to insufficient DNA quantity or quality or missing clinical information 1056 specimens were excluded for further analysis. Finally, 16,609 subjects were genotyped for the rs4680 polymorphism and included in the analysis (5886 patients with PD and 10,723 healthy controls).

| Table 1 Characteristics of subjects |
|--------------------------------------|
| **PD** | **Controls** |
| n | Sex ratio | AAO | n | Sex ratio | Age at inclusion |
| All | 5886 | 1.5 | 57.6±13.8 | 10723 | 1.01 | 60.0±10.1 |
| US | 937 | 1.5 | 57.8±13.2 | 3033 | 0.89 | 63.3±10.1 |
| UK | 1648 | 1.4 | 64.2±12.4 | 2699 | 1.07 | 53.0±0.0 |
| NL | 744 | 1.8 | 55.6±11.8 | 2019 | 0.79 | 55.7±5.8 |
| France | 1031 | 1.3 | 48.4±13.2 | 2061 | 1.20 | 73.0±6.4 |
| Germany | 1526 | 1.5 | 57.4±13.0 | 911 | 1.14 | 50.2±15.7 |

AAO, age at onset; n, number of subjects; NL, Netherlands; Sex ratio, male/female; PD, Parkinson’s disease; US, North-American.
The characteristics of subjects in the five cohorts are summarised in table 1. The mean AAO for patients with PD was 57.6±13.8 years. Cohorts of patients with PD were significantly different in terms of AAO (p<0.001) and sex ratio (p=0.04). The mean AAO was also significantly different between gender (male 57.1±13.7, female 58.3±13.9, p=0.001). Subsequent analyses thus included gender and cohorts in the multivariate model.

**Distribution of the COMT polymorphism**

The distribution of the Val158Met polymorphism in the dataset is described in table 2. The distribution of the single nucleotide polymorphism (SNP) was in Hardy-Weinberg equilibrium in patients (p=0.44) and controls groups (p=0.25). The distribution of genotypes (Val/Val, Val/Met and Met/Met) was similar and not significantly different in patients and controls (table 2, p=0.22). However, genotype distributions differed significantly among cohorts (p<0.001). The multivariate analysis including gender, cohorts and the age of PD and controls in the model found no significant association between the Val158Met polymorphism and PD (p=0.22). Altogether, these results failed to find an association between rs4680 and PD in a large population of Caucasian patients with PD and controls.

**AAO and COMT polymorphism**

The AAO was analysed assuming a genetic codominant model for the Val158Met COMT polymorphism in accordance with its codominant effect on the enzyme activity. A significant difference of AAO was found for the French (47.9±13.3 for Val/Val compared with 50.2±13.1 for Met/Met, p=0.04) and the US samples (56.2±13.4 for Val/Val compared with 59.5±12.7 for Met/Met, p=0.03). For the UK, Dutch and German samples no significant changes could be found (data not shown).

The univariate analysis for the whole PD sample (n=5886) found a significant difference of AAO according to genotype with an earlier AAO for those carrying the Val158 allele, corresponding to the high enzyme activity (table 3, p=0.04). The multivariate analysis confirmed the significant association of the AAO with the COMT polymorphism when cohorts and gender were included in the model (p=0.03). The difference of AAO was 1.2 years earlier for patients with the Val/Val genotype compared with patients with the Met/Met genotype (57.1±13.9 vs 58.3±13.5, p=0.017). Interestingly, this difference was higher in male patients (56.0±14.1 for Val/Val compared with 57.9±13.6 for Met/Met, p=0.007) than in female patients (58.6±13.4 for Val/Val compared with 58.8±13.3 for Met/Met, p=0.81) (table 3).

**DISCUSSION**

This is the largest study in which the COMT polymorphism rs4680 (Val158Met) was genotyped in PD in 16609 patients and controls from different European and North American samples. We show that the rs4680 polymorphism is a genetic modifier of the AAO in patients with idiopathic PD. Our results suggest a codominant effect of the COMT Val158Met polymorphism resulting in a modification of the AAO by 1.2 years between extreme genotypes (Val/Val and Met/Met). This effect was significant in men but not in women with a 1.9 years difference between extreme genotypes in men. This modifying effect was not associated with an increased risk of PD associated with the Val158Met polymorphism. This result confirms, in a larger cohort, the absence of association between this polymorphism and PD risk in the Caucasian population.25–27 In the French and US samples we revealed a significant earlier AAO associated with the Val/Val genotypes. In the remaining samples from Germany, the Netherlands and the UK no significant result has been shown. A possible explanation might be that these samples were underpowered.

The effect of the COMT Val158Met polymorphism on AAO might be explained by a difference of metabolism of the endogenous dopamine in the striatum at disease onset. Indeed, patients carrying the Val158 allele (Val/Val and Val/Met) may have a reduced dopamine bioavailability because of a higher enzyme activity leading to earlier motor symptoms. Conversely, poor metabolisers (Met/Met) may have a greater dopamine bioavailability delaying their motor symptoms. The inverse U curve effect of dopamine concentration in the frontal cortex28 was elegantly validated in studies of working memory in healthy controls and schizophrenic patients demonstrating that the Val158Met COMT polymorphism has indeed functional consequences on brain function.29 30 In PD, studies on the impact of the Val158Met polymorphism on non-motor symptoms have produced conflicting results.7–11 No evidence was found for an association between the Val158Met genotype and daytime sleepiness or on neuropsychological measures of attention and executive function.9 10 Other studies showed that the genotype directly affects executive function in early stage PD, Val/Val patients have less frontoparietal activation on fMRI11 and better performance on executive tasks.8 11 A pharmacogenetic study showed that the COMT polymorphism determines the acute response to entacapone,31 although the motor response to levodopa alone was not modified by the COMT polymorphism.31 32 These results collectively show that the COMT polymorphism modifies the PD phenotype. Considering its frequency, it might have to be taken into account in the clinical management of patients with PD.

An interesting result in our study was the gender difference of the COMT genotype effect on AAO. The AAO was not significantly different in women whereas it was 1.9 years earlier in men

---

### Table 2: Distribution of the COMT Val158Met polymorphism in PD and controls

| Genotype   | Total (%) (n) | Control (%) (n) | PD (%) (n) | p Value |
|------------|---------------|----------------|------------|---------|
| Val/Val    | 23.7 (3943)   | 23.6 (2526)    | 24.1 (1417) | 0.22    |
| Val/Met    | 49.5 (8214)   | 49.5 (5303)    | 49.5 (2911) |         |
| Met/Met    | 26.8 (4452)   | 27.0 (2894)    | 26.5 (1558) |         |

Val: homozygous for the Val158 allele; Met: heterozygous; Met/Met: homozygous for the Met158 allele. p Value: multivariate analysis (see material and methods).

### Table 3: Age at onset in patients with PD according to COMT Val158Met genotype

| Genotype   | Univariate p value | Multivariate p value |
|------------|--------------------|----------------------|
| Total      | 0.041              | 0.026*               |
| Men        | 0.013              | 0.007**              |
| Women      | 0.29               | 0.81**               |

*Multivariate model including cohorts and gender as cofactors.

**Multivariate model including cohorts as cofactor.

Val: homozygous for the Val158 allele; Val/Met: heterozygous; Met/Met: homozygous for the Met158 allele.

COMT, catechol-O-methyltransferase; PD, Parkinson’s disease.
with the Val/Val genotype compared with the Met/Met genotype. A sexually dimorphic autosomal genetic association of the COMT gene has been well-recognized in psychiatric disorders but has not yet been described in PD. One of the best-replicated findings was the association of low enzymatic activity with obsessive-compulsive disorder in men, but not in women. In postmortem studies, the dorsolateral prefrontal cortex of women had lower COMT activity than men. Further evidence for gender differences comes from COMT knockout mice (COMT-/-). In this model dopamine levels in the frontal cortex are significantly increased in male COMT-/- mice compared with wild-type mice, but not in female COMT-/- mice. Sex hormones, especially oestrogen, probably contribute to explain gender differences. Oestrogens inhibit COMT mRNA expression in cells expressing oestrogen receptors. However the oestrogen hypothesis might only be a part of the explanation of the gender dimorphism in our study because (1) oestrogen levels fall in postmenopausal women, the age at which PD commonly occurs and (2) in mid-age men the COMT protein and activity levels rise considerably, despite steady oestriol levels within this period. Bearing this in mind further pathophysiological mechanism could be responsible for the sexual dimorphism like additional gene implication or epigenetic regulation. A candidate gene involved in gender differences could be the monoamine oxidase B (MAOB; OMIM 309860), an X linked gene, which also participates in dopamine metabolism. The MAOB brain activity increases with age and its activity is regulated by epigenetic factors. Different SNPs of the MAOB and the combination of genotypes at risk for the MAOB and the COMT gene were suspected to be associated with PD. Interestingly, one MAOB SNP (rs1799836) was available in French patients with PD (n=992). In this subset, no significant association was found between AAO and this MAOB SNP either alone or in combination with the COMTrs4680 (data not shown).

Our study may have some limitations although statistical biases were carefully avoided by performing multivariate analyses adjusting for cohort origin and gender. Because non-motor—and non-dopaminergic symptoms—may precede motor symptoms in PD, disease onset might not adequately reflect dopaminergic denervation in the striatum that might be modified by the COMT. Finally, other environmental modifiers, like tobacco, are also likely to contribute to the development of PD symptoms but environmental factors were not available in our dataset. Genetic forms of PD as well as genetic susceptibility factors such as mutations in the galactocerebrosidase gene were not systematically screened. Indeed, an association between heterozygous galactocerebrosidase gene mutation and the AAO has been suspected in PD. Future studies must integrate the effects of environmental and genetic factors, including the COMT polymorphism, that could affect the bioavailability of dopamine in general, and especially in individuals at risk for PD.

In conclusion, our data indicate that the COMT polymorphism rs4680 (Val158Met) is a genetic modifier of AAO in patients with PD, with a higher effect in male patients than in female patients. This may be important for future diagnostic and therapeutic strategies.

Author affiliations

1INSERM, UMR 5975, CR-ICM, Paris, France
2UMPC University Paris 06, UMR 5975, CR-ICM, Pitié-Salpêtrière Hospital, Paris, France
3CNRS UMR 7225, CR-ICM, Pitié-Salpêtrière Hospital, Paris, France
4Assistance Publique Hôpitaux de Paris, Département de Génétique et Cytogénétique, Hôpital de la Pitié-Salpêtrière, Paris, France
5INSERM, CIC-9503, Hôpital de la Pitié-Salpêtrière, Paris, France
6Assistance Publique Hôpitaux de Paris, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France
7Department of Neurology, University Hospital Würzburg, Würzburg, Germany
8Assistance Publique Hôpitaux de Paris, Department of Biostatistics, Hôpital de la Pitié-Salpêtrière, Paris, France
9Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda Maryland, USA
10INSERM U1043, CPTIP, Toulouse, France
11Paul Sabatier University, Toulouse, France
12Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
13Department of Clinical Genetics Section of Medical Genomics, VU Medical Center, Amsterdam, Netherlands
14Institute of Experimental Medicine, Christian-Albrechts University, Kiel, Germany
15Assistance Publique Hôpitaux de Paris, Department of Pharmacology, Hôpital de la Pitié-Salpêtrière, Paris, France
16Faculté de Médecine de Tunis, Université de Tunis El Manar, Centre National de Pharmacovigilance de Tunis, Tunisie
17Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
18Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
19Department of Neurology, UZH-H, Campus Kiel; Christian-Albrechts-University, Kiel, Germany
20Hôpital Gabriel Montpied, CHU de Grenoble, Department of Neurology, Clermont-Ferrand, France
21CHU de Grenoble, Department of Neurology, Grenoble, France
22CHU de Nantes, Centre d’Investigation Clinique, Nantes, France
23Hôpital Haut-Lévêque, Department of Neurology, Pessac, France
24INSERM, U744, Lille, France
25Institut Pasteur de Lille, Lille, France
26Université Lille-Nord de France, Lille, France
27Université Pierre et Marie Curie—Paris 6, CNRS 7225 CRICM, ER4-UPMC Modélisation en recherche clinique, Hôpital Pitié-Salpêtrière, Paris, France
28INSERM UMR 5797, Neuropédiatriologie, Paris, France
29INSERM U087, Université Bordeaux Sédgale, Bordeaux, France
30“Movement Disorders and Basel Garglia: Pathophysiology and experimental Therapeutics”, INSERM, UMR 5797, Paris, France

Acknowledgements We thank all study participants for their cooperation. The technical assistance of the DNA and cell bank of the Federative Institute for Neuroscience is gratefully acknowledged and the authors wish to thank Dr Merle Ruberg for critical review of the manuscript. We also thank the members of the French 3C Consortium: Annick Alpérovitch, Claudine Ber, Christophe Tzourio and Philippe Amouyel for allowing us to use part of the 3C cohort. This study was supported by grants from the German Federal Ministry of Education and Research (01ER01), the Medical Faculty of the Kiel University, the Cluster of Excellence "Inflammation at Interfaces,” Christian-Albrechts University, Kiel, Ministry for Science, Commerce and Transportation of Schleswig-Holstein, Germany, and the German National Genome Research Network (NGFN) through the POGEN biobank (BMF 01GR0468). CK is a recipient of a career development award from the Hermann and Lilly Schilling Foundation. The US work was supported in part by the Intramural Research Programs of the National Institute on Aging project numbers 201 AG000949-02. Portions of this study used the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, Md. (http://biowulf.nih.gov).

Collaborators The French Parkinson’s Disease Genetics Study Group includes, Y Agid: AP-HP, Hôpital de la Pitié-Salpêtrière, Department of Neurology, 75013 Paris, France; M Arheim: AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique et Cytogénétique, Centre de Génétique Moléculaire et Chromosomique, 75013 Paris, France; A-M Bonnet: AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Neurologie, 75013 Paris, France; M Borg: Service de Neurologie, Hôpital Pasteur, Nice, France; A. Brice: AP-HP, Hôpital de la Pitié-Salpêtrière, Department of Neurology, 75013 Paris, France, AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique et Cytogénétique, Centre de Génétique Moléculaire et Chromosomique, 75013 Paris, France; E Brosilow: University of Lyon; Hospices Civils de Lyon, Neurological Hospital, Lyon, France; J-C Coutot: INSERM, Centre d’Investigation Clinique CIC-9503, Hôpital de la Pitié-Salpêtrière, Paris, France; Ph. Damier: CHU Nantes, CIC0004, Department of Neurology, Nantes, France; +A. Destée: Université Lille-Nord de France, CHRU de Lille, Neurologie, Hôpital Roger Salengro, Lille Cedex, France; A Duru: AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique et Cytogénétique, Centre de Génétique Moléculaire et Chromosomique, 75013 Paris, France; F Durif: Hôpital Gabriel Montpied, Department of Neurology, Clermont-Ferrand, France; S Klebe: AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique et Cytogénétique, Centre de Génétique Moléculaire et Chromosomique, 75013 Paris, France; E Lehmann: AP-HP, Hôpital de...
Movement disorders

la Pitié-Salpêtrière, Département de Genétique et Cytogénétique, Centre de Génétique Moléculaire et Chromosomique, 75013 Paris, France; M Martinet: INSERM U636, CTIP, Toulouse, France; C Penet: INSERM, U975, 75013 Paris, France; P Pollak: CHU de Grenoble, Department of Neurology, Grenoble, France; P Koll: CHU de Grenoble, Department of Neurology, University of Grenoble, France; M Rosci: Departments of Clinical Pharmacology and Neurosciences, Hospital and University Paul Sabatier of Toulouse, France; F Tison: Hôpital Hôtel-Lêvêque, Département de Neurologie, Pessac, France; C Tranchant: Département de Neurologie, Hôpital Civil, Strasbourg, France; M Vérin: Service de Neurologie, Hôpital Pontchaillou, CHU de Rennes, Rennes, France; F Viallat: Service de Neurologie, CHU La Timone, Marseille, France; and M Viala: Hôpital de la Pitié-Salpêtrière, Département de Neurologie, 75013 Paris, France. International Parkinson’s Disease Genetics Consortium (IPDGC) includes—Michael A Nalls: Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA; Vincent Plagnol: UCL Genetics Institute, Gower Place, London, WC1E 6BT, UK; Jose M Brás: Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG; Dena G Hernandez: Laboratory of Neurogenetics, National Institutes of Health, Bethesda, MD 20892, USA, Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG; Manu Sharma: INSERM UMR 1043, CTIP, Toulouse, France; Una-Marie Sheerin: Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG; Mohamed Saad: INSERM UMR 1043, CTIP, Toulouse, France, Paul Sabatier University, Toulouse, France; Xavier Stréblow: CR-CAM, Department of Neurogenetics, Section of Neurogenetics, VU University Medical Centre, Amsterdam, The Netherlands; Claudia Schulte: Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, and DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany; Suzanne Lesage: INSERM, UMR_S575 (Formerly UMR_S579), Paris, France, Université Pierre et Marie Curie-Paris, Centre d’Investigation Clinique de l’Institut de la Moelle épinière, UMR-S579, Paris, France, CNRS, UMR 7225, Paris, France; Sigurtaug Sveinbjörnsdóttir: Department of Neurology, Landsjóshótel University Hospital, Reykjavík, Iceland, Department of Neurology, MEHT Broomfield Hospital, Chelmford, Essex, UK, Queen Mary College, University of London, London, UK; Philippe Amouyel: INSERM U744, Lille, France, Institut Pasteur de Lille, Université de Lille Nord, Lille, France; Samapth Arapalli: Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA; Gavin Band: Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7LJ, UK; Roger A Barker: Department of Neurology, Addenbrooke’s Hospital, University of Cambridge, Hills Road, Cambridge CB2 2QZ; Céline Béllenguez: Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7LJ, UK; Yoav Ben-Shlomo: Department of Social Medicine, Bristol University, Henk W Beers: Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands; Daniela Berg: Department of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA, Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG; Daniela Berg: Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, and DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany; Kaißal Bhatia: Department of Motor Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG; Sabine Bay MA de Saude, Department of Neurology, Hospital de Síndromes Progressivos, Lisbon, Portugal; Alessandro Band: Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7LJ, UK; Paul Sabatier University of Toulouse, Toulouse, France; Kiel, Germany; Pálmi V Jónsson: Department of Geriatrics, Landspítali University Hospital, Reykjavík, Iceland; Carl Counsell: University of Aberdeen, Division of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG; James Fowler: Laboratory of Neurogenetics, National Institutes of Health, Bethesda, MD 20892, USA, Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG; Alain Goate: Department of Psychiatry, Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA; Emma Gray: Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge, CB10 1SA, UK; Jiri Gabor: Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG; John P National Hospital West, St Pancras, London, WC1N 3BG, Department of Neurology, NHS Trust, London, 1st floor, Burlington Danes Building, Hammersmith Hospital, Du Cane Road, W12 ONN London, UK; Bar D van Dijk: Department of Neurology and Alzheimer Center, University Medical Center, Amsterdam, The Netherlands; Allister Dillman: Department of Molecular Genetics, UCL Institute of Neurology, Queen Square, London, WC1N 3BG; Benjamin El ia: Department of Clinical Neurology, 75013 Paris, France; Huw Morris: MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University School of Medicine, Cardiff, CF4 4XN, UK; Karen E Morrison: School of Clinical and Experimental Medicine, University of Birmingham, Edgbaston, Birmingham B15 2T7, Neurosciences Department, Queen Elizabeth Hospital, University Hospitals
Medical genomics, the Prinse Beatrix Fonds (http://www.prinsebeatrixfonds.nl) for sponsoring this work. This study utilised the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, Md. (http://biowulf.nih.gov). DNA panels and samples from the NINDS Human Genetic Resource Center DNA and Cell Line Repository (http://ccr.coriell.org/; ninds) were used in this study, as well as clinical data. The submitters that contributed samples are acknowledged in detailed descriptions of each panel (http://ccr.coriell.org/sections/Collections/NINDS/?SsId=10). The authors thank The French Parkinson’s Disease Genetics Study Group: Y Agid, M Anheim, A-M Bonnet, M Borg, A Brice, E Broussole, J-C Corvol, Ph Damier, A Destee, A Durr, F Durif, S Durr, F E Lohmann, M Martinez, P Pollak, O Rascol, F Troncoso, C Vincent, C M Vérin, F Viallet and M Vidalilet. The authors thank the members of the French 3C consortium: Drs Amrick Alperovitch, Claudine Berr, Christopher Tzourio and Jean-Charles Lambert for giving us the possibility to use part of the 3C cohort; and Drs M Lathrop and D Zelenika for their support in generating the genome-wide molecular data. The UK brain samples for the gene expression studies were obtained from the MRC Sudden Death Brain Bank in Edinburgh. This study makes use of GWA data generated by the Welcome Trust Case Control Consortium 2 (WTCCC2) on UK PD cases and on UK controls from the 1958 Birth Cohort (SBBC) and National Blood Service (NBS). UK population control data was made available through WTCCC1. We thank Jeffrey Barnett for assistance with the design of the Immunochip.

Competing interests None.

Ethics approval Local ethics committees.

Disclosure Dr Klebe received funding from the Deutsche Forschungsgemeinschaft (DFG) (DFG KI 1433/2-1). He received royalties from Thieme publishers. Dr Gollmar reports no disclosures. Dr Nalls reports no disclosures. Dr Martinez reports no disclosures. Prof Singleton reports no disclosures. Dr Bras reports no disclosures. Dr Hardy consults for Eisai Pharmaceuticals. Dr Javier Simon-Sanchez reports no disclosures. Dr Peter Heutink reports no disclosures. Dr Kuhlenbaumer received grants from the Deutsche Forschungsgemeinschaft, the regional government and the Christian-Albrechts-University Kiel. Prof Klein is supported by grants from the Hermann and Lilly Shilling Foundation and from the BMBF (01G02001), and the Bachmann-Strauss Dysotonia & Parkinson Foundation. She also received consulting fees from Centogene and honoraria for speaking from Shire and Merz Pharma. Dr Charfi reports no disclosures. Dr Johann Hagemann receives funding from Bachmann-Strauss Dysotonia Parkinson. Prof Gasser serves as an editorial board member of Parkinsonism and Related Disorders, Journal of Parkinson’s Disease and Neurogenetics and is funded by Novartis Pharma, the Federal Ministry of Education and Research (BMBF) (NGFN-Plus and ERA-Net NEURON), the Helmholtz Association (Helma, Helmholtz Alliance for Health in an Ageing Society) and the European Community (MeFoPa, Mendelian Forms of Parkinsonism). He received speakers’ honoraria from Novartis, Merck-Serono, Schwarz Pharma, Boehringer Ingelheim and Valeant Pharma and royalties for his consulting activities from Cefalon Pharma and Merck-Serono. Prof. Gasser holds a patent concerning the LRKK2 gene and neurodegenerative diseases. I Wurster reports funding by GlaxoSmithKline for travel to a Congress. no disclosures. Dr Lesage reports no disclosures. Dr Lorenz reports no disclosures. Dr Deuchsl has received lecture fees from Genom, Lundbeck, Teva and Pfizer and has been serving as a consultant for EVA. He received royalties from Thieme publishers. He is a government employee and he receives through his institution funding for his research from the German Research Council, the German Ministry of Education and Health and Medtronic. Dr Saad reports no disclosures. Dr Durif reports no disclosures. Prof Pollak received speaker honoraria from Novartis and Medtronic. Prof Damier served on the European advisory board for Lundbeck-Teva and received honoraria for conferences given on behalf of Novartis and Glaxo SmithKline. Prof Tison has received speaker honoraria from UCB, Novartis, Lundbeck, GSK, Boehringer Ingelheim and Aquentant; served on scientific advisory board for Novartis, Addex pharmaceuticals; received research grant from Novartis and received funding for travel from Novartis, UCB, Lundbeck. Dr Durr received honoraria from Pfizer Inc. for participating to the Global Tau Risk Genetics Advisory Board, and received research support for the International Agency for Research. Dr Mabrouk is funded by the Fondation pour la recherche médicale (FRM, France) and reports no disclosures. Dr Amouyel received honoraria from serving on the medical advisory board of Total and Ipsen, for lectures for Sanofi, Pfizer, Servier and holds stocks from Genoscreen. Dr Lambert reports no disclosures. Dr Tzourio reports no disclosures. Dr Charbonnier-Beaupe reports no disclosures. Ms Tahiri reports no disclosures. Prof Viallat had institutional (ANR, INSERM, INSPERM) and Patient’s association (France Parkinson) research grants. Prof. Principe received honoraria from the Wolfont Foundation for reviewing scientific project, and received research support from the French Agency for Research, Programme Hospitalier de Recherche Clinique, European Community and patients associations. Dr Jean-Christophe Corvol received research grants from INSERM and APHP, and received speaker’s honoraria and travel reimbursements from Lundbeck, Biogen and Schering-Plough.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.

REFERENCES
1. Fodoros Y, Wetterberg L. The inheritance of human erythrocyte catechol-O-methyltransferase activity. Clin Genet 1981;19:392–5.
2. Weinsilboum R, Raymond F. Variations in catechol-O-methyltransferase in inbred strains of rats. Neuropsychopharmacology 1977;16:703–6.
3. Lotta T, Virdgen J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995;34:4202–10.
4. Lachman HM, Papolos DF, Saito T, et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243–50.
5. McLeod HL, Syvancen AC, Githanga J, et al. Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics 1998;8:195–9.
6. Hernan MA, Checkoway H, O’Brien R, et al. MA08 intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD. Neurology 2002;58:1381–7.
7. Eerola J, Launes J, Hellstrom O, et al. Apolipoprotein E (ApoE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson’s disease in Finland. Neurosci Lett 2002;330:296–8.
8. Foltyne T, Goldberg TE, Lewis SG, et al. Planning ability in Parkinson’s disease is influenced by the COMT val158met polymorphism. Mov Disord 2004;19:885–91.
9. Hoogland J, de Bie RM, Williams-Gray CH, et al. Catechol-O-methyltransferase val158met and cognitive function in Parkinson’s disease. Sleep 2006;29:108–11.
10. Williams-Gray CH, Hampshire A, Robbins TW, et al. Catechol-O-methyltransferase Val158Met genotype influences frontostriatal activity during planning in patients with Parkinson’s disease. J Neurol 2007;254:4832–8.
11. Hughes AJ, Daniel SE, Kifflord L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.
12. 3C Study Group. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology 2003;22:316–25.
13. Krawczak M, Nikolaus S, von Eberstein H, et al. PopGen: population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. Community Genet 2006;9:55–61.
14. Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 2011;377:641–9.
15. International Parkinson’s Disease Genomics Consortium (IPDGC); Welcome Trust Case Control Consortium 2 (WTCCC2). A two-stage meta-analysis identifies several new loci for Parkinson’s disease. PLoS Genet 2011;7:e1002142.
16. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 2009;41:1308–12.
17. Simon-Sanchez J, van Hillen JH, van de Warrenburg B, et al. Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet 2011;19:655–61.
18. Spencer CC, Plagnol V, Strange A, et al. Dissection of the genetics of Parkinson’s disease identifies an additional association of SNCA and multiple associated haplotypes at 1q21.2. Hum Mol Genet 2011;20:345–53.
19. Saad M, Lesage S, Saint-Pierre A, et al. Genome-wide association study confirms BST1 and suggests a focus on 12q24 as the risk loci for Parkinson’s disease in the European population. Hum Mol Genet 2011;20:615–27.
20. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061–73.
21. Li Y, Willer CJ, Ding J, et al. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010;34:816–34.
22. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysiscorrectsfor stratification in genome-wide association studies. Nat Genet 2006;38:904–9.
23. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559–75.

J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2012-304475 on 13 February 2013. Downloaded from http://jnnp.bmj.com/ on October 19, 2020 by guest. Protected by copyright.
25 Goudreau JL, Maraganore DM, Farrer MJ, et al. Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson’s disease. Mov Disord 2002;17:1305–11.

26 Hoda F, Nicholl D, Bennett P, et al. No association between Parkinson’s disease and low-activity alleles of catechol O-methyltransferase. Biochem Biophys Res Commun 1996;228:780–4.

27 Kalinderi K, Fidani L, Kourtessi G, et al. No association of the Val158Met COMT polymorphism with Parkinson’s disease in the Greek population. Eur J Neurol 2008;15:e83.

28 Goldman-Rakic PS, Muly EC III, Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 2000;31:295–301.

29 Williams-Gray CH, Hampshire A, Barker RA, et al. Attentional control in Parkinson’s disease is dependent on COMT val 158 met genotype. Brain 2008;131:397–408.

30 Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 2006;62:141–51.

31 Convol JC, Bonnet C, Charbonnier-Beaupel F, et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson disease in men: case-control study and meta-analysis. Mol Psychiatry 2007;12:556–61.

32 Contin M, Martinelli P, Mochi M, et al. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson’s disease. Mov Disord 2005;20:734–9.

33 Denys D, Van Nieuwerburgh F, Deforce D, et al. Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive-compulsive disorder in males. Eur Neuropsychopharmacol 2006;16:446–50.

34 Poyurovsky M, Michaelovsky E, Frisch A, et al. COMT Val158Met polymorphism in schizophrenia with obsessive-compulsive disorder: a case-control study. Neurosci Lett 2005;389:21–4.

35 Pooley EC, Fineberg N, Harrison PJ. The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis. Mol Psychiatry 2007;12:556–61.

36 Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004;75:807–21.

37 Gogos JA, Morgan M, Luine V, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998;95:9991–6.

38 Harrison PJ, Tunbridge EM. Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology 2008;33:397–45.

39 Tunbridge EM, Weickert CS, Kleinman JE, et al. Catechol-o-methyltransferase enzyme activity and protein expression in human prefrontal cortex across the postnatal lifespan. Cereb Cortex 2007;17:1206–12.

40 Bjornerem A, Straume B, Midtby M, et al. Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic diseases in a general population: the Tromsø Study. J Clin Endocrinol Metab 2004;89:6039–47.

41 Kaminsky Z, Wang SC, Petronis A. Complex disease, gender and epigenetics. Annu Rev Med 2006;38:330–44.

42 Volchkovskii IA, Shemyakov SE, TunyginVV, et al. Comparative analysis of age-related changes in activities of monoamine oxidase-B and antioxidant defense enzymes in various structures of human brain. Bull Exp Biol Med 2001;132:760–2.

43 Launay JM, Del Pino M, Chironi G, et al. Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation. PloS One 2009;4:e7959.

44 Gao X, Scott WK, Wang G, et al. Gene–gene interaction between FGF20 and MAOB in Parkinson disease. Ann Hum Genet 2006;70:343–50.

45 Wu RM, Cheng CW, Chen KH, et al. The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese. Neurology 2001;56:375–82.

46 Nichols WC, Pankratz N, Marek DK, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009;72:310–16.